Skip to main content

Table 4 ECG summary parameters (means in ms) for day 1, day 3 pre-dose, day 3 post-dose and day 7 for treatment with three doses of Eurartesim® [N = 1,002] based on central laboratory readings

From: Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania

 

PR

HR

QT

QTcB

QTcF

95% *Confidence interval

*P-value

Visit

       

Day 1 (baseline)

134. 2

104. 6

331. 9

429. 6

393. 3

-

-

Day 3 pre-dose 3

138. 3

92. 5

355. 4

434. 2

411. 2

-

-

Day 3 post-dose 3

140. 5

91. 6

366. 1

444. 1

415. 8

-

-

Day 7

137. 6

94. 2

346. 2

428. 2

398. 6

-

-

Δ Days 1 to 3 pre-dose

4. 1

−12. 1

23. 5

4. 6

17. 9

16 ,19

<0. 001

Δ Days 1 to 3 post-dose

6. 3

−13. 1

34. 2

14. 6

22. 5

21,24

<0. 001

Δ Days 1 to 7

3. 3

−10. 3

14. 2

-. 31

5. 3

4,7

<0. 001

  1. *Confidence intervals and *P-values were calculated for the mean change in QTcF.